National Psoriasis Foundation
Advertisement

Smoking makes psoriatic arthritis drugs less effective

By Melissa Leavitt

Smoking may make some treatments for psoriatic arthritis less effective, according to the results of a recent study.

In an analysis of treatment outcomes for patients taking certain kinds of biologics, a team of Danish researchers found that smokers do not improve as much, and do not stick with the treatment for as long, as nonsmokers.

The study, published last month in Annals of the Rheumatic Diseases, examined the impact of smoking on treatment with the tumor necrosis factor-alpha (TNF-alpha) inhibitor drugs Enbrel (etanercept), Remicade (infliximab) and Humira (adalimumab). A cytokine, or protein, involved in inflammation, TNF-alpha is a common target for psoriatic disease treatments. 

Using a Danish patient database called the DANBIO registry, researchers studied 1,148 people taking TNF-alpha inhibitors for psoriatic arthritis. Among this group, 33 percent were current smokers and 41 percent had never smoked. The remaining 26 percent were classified as previous smokers, who stopped smoking by the time they started treatment.

Before starting treatment, smokers were in poorer health than never-smokers or previous smokers, according to the study. They also had been diagnosed with psoriatic arthritis more recently, the researchers report, which could indicate that their symptoms were more aggressive.

After six months of treatment, only 24 percent of smokers improved by 20 percent (a measurement known as ACR20), compared with 33 percent of never-smokers, according to the study results. Using a different measure of improvement, researchers found that only 23 percent of smokers achieved EULAR-good-response after 6 months, compared with 34 percent of never-smokers. EULAR-good-response is determined by the number of swollen and tender joints a patient has. 

Researchers also found that smokers stayed on TNF-alpha inhibitors for less time than nonsmokers. The median treatment duration was 1.56 years for smokers, compared with 2.43 years for never-smokers. 

Therapy with TNF-alpha inhibitors is generally considered to be an effective treatment for psoriatic arthritis, the researchers note. However, they explain, previous studies have shown that only approximately 60 percent of patients achieve ACR20 while on these drugs. This study indicates that smoking may be a lifestyle factor that can make TNF-alpha treatment less effective.

 

Advertisement


Did you enjoy this article? Want to read more?

Check out more from Psoriasis Advance »

Advertisement

 

Copyright © 1996-2013 National Psoriasis Foundation/USA

Any duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of National Psoriasis Foundation. National Psoriasis Foundation does not endorse or accept any responsibility for the content of external websites.

National Psoriasis Foundation | 6600 SW 92nd Ave., Suite 300, Portland, OR 97223
getinfo@psoraisis.org | www.psoriasis.org

National Psoriasis FoundationNational Psoriasis Foundation Our Mission: To drive efforts to cure psoriatic disease and improve the lives of those affected.

CONTACT US

getinfo@psoriasis.org
800-723-9166

National Office:
6600 SW 92nd Ave., Ste. 300
Portland, OR 97223


Washington D.C. Office:
1800 Diagonal Rd., Ste. 360
Alexandria, VA 22314


Site Feedback »

Copyright © 1996-2014 National Psoriasis Foundation/USA

Any duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of National Psoriasis Foundation.

The National Psoriasis Foundation does not endorse or accept any responsibility for the content of external websites.

The National Psoriasis Foundation does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

Member of Community Health Charities National Health CouncilFour Star Charity Navigator Rating